- Home
- BIIB vs CBOE Comparison
BIIB vs CBOE Comparison
Compare BIIB & CBOE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CBOE
- Stock Information
- Founded
- BIIB 1978
- CBOE 1973
- Country
- BIIB United States
- CBOE United States
- Employees
- BIIB N/A
- CBOE N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CBOE Investment Bankers/Brokers/Service
- Sector
- BIIB Health Care
- CBOE Finance
- Exchange
- BIIB Nasdaq
- CBOE Nasdaq
- Market Cap
- BIIB 18.7B
- CBOE 25.6B
- IPO Year
- BIIB 1991
- CBOE 2010
- Fundamental
- Price
- BIIB $142.38
- CBOE $235.93
- Analyst Decision
- BIIB Buy
- CBOE Hold
- Analyst Count
- BIIB 25
- CBOE 13
- Target Price
- BIIB $183.05
- CBOE $234.15
- AVG Volume (30 Days)
- BIIB 1.8M
- CBOE 794.9K
- Earning Date
- BIIB 10-30-2025
- CBOE 10-31-2025
- Dividend Yield
- BIIB N/A
- CBOE 1.22%
- EPS Growth
- BIIB 31.67
- CBOE 18.01
- EPS
- BIIB 10.45
- CBOE 8.52
- Revenue
- BIIB $9,997,000,000.00
- CBOE $4,531,800,000.00
- Revenue This Year
- BIIB $2.00
- CBOE N/A
- Revenue Next Year
- BIIB N/A
- CBOE $4.38
- P/E Ratio
- BIIB $13.61
- CBOE $27.69
- Revenue Growth
- BIIB 3.36
- CBOE 18.98
- 52 Week Low
- BIIB $110.04
- CBOE $187.30
- 52 Week High
- BIIB $192.16
- CBOE $255.27
- Technical
- Relative Strength Index (RSI)
- BIIB 46.57
- CBOE 43.39
- Support Level
- BIIB $142.20
- CBOE $234.72
- Resistance Level
- BIIB $160.20
- CBOE $246.64
- Average True Range (ATR)
- BIIB 4.83
- CBOE 5.24
- MACD
- BIIB -1.15
- CBOE -0.30
- Stochastic Oscillator
- BIIB 28.17
- CBOE 8.48
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CBOE Cboe Global Markets Inc.
Founded in 1973, Cboe controls the largest option exchange in the US, which provides around 60% of the firm's revenue. The company is best known for its proprietary S&P 500 and VIX index options, which it offers through an exclusive contract with S&P Global. The firm moved into US and European equities through the $3.4 billion acquisition of BATS in 2017. Cboe has continued to look to expand internationally, using acquisitions to build a presence in both Canada and Australia.